Best Biologic Therapy for IBD with Diffuse Arthropathy

First-Line Treatment Strategy

• The American College of Gastroenterology recommends infliximab and adalimumab as first-line biologic therapy for patients with both IBD and arthropathy, due to their efficacy in treating both conditions simultaneously 1, 2, 3
• The use of biosimilars for infliximab and adalimumab is supported due to their equivalent effectiveness and safety at reduced costs 2, 3
• Certolizumab pegol is a viable TNF inhibitor option for Crohn's disease and axial spondyloarthritis 2, 3
• Golimumab is specifically recommended for ulcerative colitis with axial spondyloarthritis 1, 3

Type of Arthropathy Matters

• For moderate-to-severe peripheral arthritis, TNF inhibitors (infliximab, adalimumab) are recommended as first-line therapy 4, 5
• Sulfasalazine (2-3 g/day) can be considered for mild peripheral arthropathy with ulcerative colitis 1
• Methotrexate is not effective for axial disease but can be considered for peripheral arthropathy in Crohn's disease 1, 2

Second-Line Options After TNF Inhibitor Failure

• Switch to JAK inhibitors (tofacitinib or upadacitinib) for primary non-response to TNF inhibitors 1, 6, 2
• Ustekinumab can be considered as a second-line option, although evidence is less robust for arthropathy 4, 5

Therapies to Avoid or Use with Extreme Caution

• Etanercept should not be used due to its ineffectiveness in active Crohn's disease and potential to trigger new-onset Crohn's disease 2, 3
• Anti-IL-17 agents (secukinumab, ixekizumab) should not be used in patients with active IBD or IBD in remission, as they can cause new-onset IBD or exacerbate existing disease 1, 7
• Vedolizumab is not recommended for IBD with arthropathy due to its lack of efficacy for musculoskeletal manifestations 4, 5